Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

目录号：S2680 中文名称：依鲁替尼

Ibrutinib (PCI-32765) Chemical Structure

CAS No. 936563-96-1

Ibrutinib (PCI-32765)是一种有效的，高选择性的Brutons tyrosine kinase (Btk)抑制剂，无细胞试验中IC50为0.5 nM，对Bmx， CSK， FGR， BRK及HCK适度有效，对EGFR， Yes， ErbB2， JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2226.41 现货
RMB 1392.54 现货
RMB 7922.62 现货
RMB 20229.3 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Ibrutinib (PCI-32765)发表文献451篇：

产品安全说明书

Target Protein Ligand抑制剂选择性比较

生物活性

产品描述 Ibrutinib (PCI-32765)是一种有效的，高选择性的Brutons tyrosine kinase (Btk)抑制剂，无细胞试验中IC50为0.5 nM，对Bmx， CSK， FGR， BRK及HCK适度有效，对EGFR， Yes， ErbB2， JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC。
靶点
BTK [1]
(Cell-free assay)		 BLK [1]
(Cell-free assay)		 Bmx [1]
(Cell-free assay)		 CSK [1]
(Cell-free assay)		 FGR [1]
(Cell-free assay)
0.5 nM 0.5 nM 0.8 nM 2.3 nM 2.3 nM
体外研究

Ibrutinib有效可逆且选择性抑制Btk酶活性。Ibrutinib作用于 BCR 通路激活的 DOHH2细胞系, 抑制Btk自磷酸化, Btk's 生理底物 PLCγ磷酸化, 和更远一点的下游激酶ERK的磷酸化，IC50分别为11 nM, 29 nM 和 13 nM。[1] Ibrutinib作用于慢性淋巴细胞白血病 (CLL) 细胞，诱导细胞毒性，这种作用存在剂量和时间依赖性。此外, Ibrutinib诱导 caspase依赖性细胞死亡通路激活，且在TLR信号后，抑制CLL细胞增殖能力。[2] 最新研究显示Ibrutinib抑制 BCR激活的原代 B细胞增殖,IC50 为8 nM，且抑制 原代单核细胞中TNFα, IL-1β 和 IL-6产量， IC50 分别为2.6 nM, 0.5 nM, 和 3.9 nM。 [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Rec1 cells M2faWGZ2dmO2aX;uJIF{e2G7 MnPENk42KM7:TR?= NVvvN45ZPiCq NHjrcFVKdmirYnn0bY9vKG:oIFz5ckBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gVoVkOSClZXzsd{BifCB{LkWgeW0hcW6ldXLheIVlKG[xcjC2JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIH3leIhw\A>? NF:1U5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNlg4Pyd-MkWyNlI5Pzd:L3G+
human WSU-NHL cells M4fvW2N6fG:2b4jpZ:Kh[XO|YYm= NIHYc5I4OiCq NIT6b4tEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBYW1VvTljMJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNFkh|ryP NUf5cYJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
human SU-DHL6 cells NFnUVWdEgXSxdH;4bYPDqGG|c3H5 MWi3NkBp NELyNmJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXS2GSFy2JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVgh|ryPLh?= NIPyc5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
human DOHH2 cells Ml;hR5l1d3SxeHnjxsBie3OjeR?= MlXXO|IhcA>? NHH0cnpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFV0iKMjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxJO69VS5? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
Sf9 cells Mk\mSpVv[3Srb36gZZN{[Xl? MnjDNUBp MXjJcohq[mm2aX;uJI9nKEy\Tj3BJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYX\0[ZIhPjBibXnud{BjgSCWUj3GVmVVKEG|c3H5MEBKSzVyPUCuNkDPxE1w M1W5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUW4OVQ4Lz5{MUm1PFU1PzxxYU6=
human Ramos cells Mn70SpVv[3Srb36gZZN{[Xl? MknRNUBp MnG4TY5pcWKrdHnvckBw\iCEdHugbY4hcHWvYX6gVoFud3NiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBRVENvZ3HtcYEzKHCqb4PwbI9zgWyjdHnvckBifCCWeYKxNlE4KGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{NCCLQ{WwQVE1KG6PLh?= NW\LO25iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
human Pfeiffer cells NIDiNXNHfW6ldHnvckBie3OjeR?= MofDO|IhcA>? NGPDWHZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBR\mWrZn\ldkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yJI5ONg>? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
Sf9 cells NX\rWY4xTnWwY4Tpc44h[XO|YYm= NHvvTYQyKGh? MkHUTY5pcWKrdHnvckBw\iCqdX3hckBnfWyuLXzlcod1cCCEVFug[ZhxemW|c3XkJIlvKFOoOTDj[YxteyC3c3nu[{BHSU1vU4LjeIll\SCyZYD0bYRmKGG|IIP1ZpN1emG2ZTDh[pRmeiB4MDDtbY5{KGK7IGTSMWZTTVRiQYPzZZnwxIxiSVO1NF0xNjVibl2u MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3OEW0O{c,OjF7NUi1OFc9N2F-
Sf9 insect cells MXrGeY5kfGmxbjDhd5NigQ>? NYrjPXhnPjBibXnudy=> MX3JR|UxKD1iMD6wNFA{KM7:TR?= M{DoO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
sf9 cells NETUd2RHfW6ldHnvckBie3OjeR?= M3T2Z2lEPTBiPTCwMlAxODNizszN MmG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N|YoRjJ5OUm0O|M3RC:jPh?=
Sf9 insect cells NUnSNmdHTnWwY4Tpc44h[XO|YYm= NWLQOpBPPjBibXnudy=> MXLJR|UxKD1iMD6wNFA{PCEQvF2= M{TZfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Sf9 insect cells NVXNeFI5TnWwY4Tpc44h[XO|YYm= MkDaOlAhdWmwcx?= NHzVUXBKSzVyIE2gNE4xODB|NDFOwG0> MlPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{K5OFYoRjJ6NEOyPVQ3RC:jPh?=
Sf9 insect cells MnTiSpVv[3Srb36gZZN{[Xl? NWHxTph2PjBibXnudy=> NWnvcXZzUUN3MDC9JFAvODByM{Sg{txO Ml\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7NU[wN|coRjJ5OUW2NFM4RC:jPh?=
Sf9 cells NGfnd4NHfW6ldHnvckBie3OjeR?= Mn21OlAhdWmwcx?= NYXFVHhMUUN3MDC9JFAvODByNDFOwG0> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNkG0N{c,OzByME[xOFM9N2F-
Sf9 cells MUTGeY5kfGmxbjDhd5NigQ>? NXq3[4J6PjBibXnudy=> MYrJR|UxKD1iMD6wNFA2KM7:TR?= NH\URXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1PFU1Pyd-MkG5OVg2PDd:L3G+
Ramos cells NIfvPI9HfW6ldHnvckBie3OjeR?= NY[4SIJnOSCq MoDyTWM2OCB;IECuNFAxPSEQvF2= NV\GV3B6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
Sf9 cells NH3rOnFHfW6ldHnvckBie3OjeR?= MWW2NEBucW6| NIO1W2JKSzVyIE2gNE4xODFizszN M3LZRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5|MEC3O|YxQDxxYU6=
Pfeiffer cells MV7DfZRwfG:6aXPpeJkh[XO|YYm= MlHZO|IhcA>? NH34NmZIUTVyIE2gNE4xODJizszN M3;NbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
B cells NGnjcndHfW6ldHnvckBie3OjeR?= NHPkTJQyKGh? MWnJR|UxKD1iMD6wNFQ3KM7:TR?= NH\0[4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK5NFk5QCd-M{CyPVA6QDh:L3G+
Sf9 insect cells M{fBN2Z2dmO2aX;uJIF{e2G7 MWOyJJRwKDZyIH3pcpM> MkXvT4khRSByLkCwOFgh|ryP MmnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
Ramos cells NF7SVlRHfW6ldHnvckBie3OjeR?= MWOxJIg> M4jUcmlEPTBiPTCwMlAxPzVizszN MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
Sf9 insect cells MVvGeY5kfGmxbjDhd5NigQ>? NXXmcG9GPjBibXnudy=> NWfTUGV3UUN3MDC9JFAvODB6IN88US=> NFv0NWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
TMD8 cells NH;tUmtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NXrkVWU4PzJiaB?= MV7JR|UxKD1iMD6wNUDPxE1? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdzNUCyN{c,Ojl5MUWwNlM9N2F-
CD19+ B cells MoOxSpVv[3Srb36gZZN{[Xl? NHjxWY0yKGh? NUO1eIloUUN3MDC9JFAvODF{IN88US=> MmnKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUe5PFIoRjJ7NEW3PVgzRC:jPh?=
Sf9 insect cells M2rmRWZ2dmO2aX;uJIF{e2G7 Mom0OlAhdWmwcx?= MonlTWM2OCB;IECuNFEzKM7:TR?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Ramos cells Ml3xSpVv[3Srb36gZZN{[Xl? NHGycnQyKGh? NXn3SYNuUUN3MDC9JFAvODF2IN88US=> NXXxTZRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 insect cells MXfGeY5kfGmxbjDhd5NigQ>? MVKxJIg> MWfJR|UxKD1iMD6wNVQ1KM7:TR?= M3fLdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{G1NFI{Lz5{OUexOVAzOzxxYU6=
Sf9 insect cells M2DWOGZ2dmO2aX;uJIF{e2G7 NILselY3OCCvaX7z M3fNNmlEPTBiPTCwMlAyPjFizszN NV\WXoNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFYyOzZpPkK5NVQ3OTN4PD;hQi=>
HCC827 cells NVO4fmtuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M{i4elczKGh? NWHpWHBJUUN3MDC9JFAvODN7IN88US=> M4Hrc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{O0OVgyLz5{OEezOFU5OTxxYU6=
PC9 cells NWDie|duTnWwY4Tpc44h[XO|YYm= MX23NkBp NWP6OVBMT0l3MDC9JFAvODVizszN M4HEN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
Sf9 cells MX7GeY5kfGmxbjDhd5NigQ>? NI\mU3E3OCCvaX7z NWq0WWZqUUN3MDC9JFAvOSEQvF2= M4qzd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEC2NVQ{Lz5|MECwOlE1OzxxYU6=
H3255 cells NEPEfGZHfW6ldHnvckBie3OjeR?= MWK3NkBp NHvGcHVIUTVyIE2gNE4yOSEQvF2= NFWyPFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BaF3 cells NIribnpHfW6ldHnvckBie3OjeR?= NIXwTZk4OiCq M{T5NGdKPTBiPTCwMlEzKM7:TR?= NFLTc2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[zNFU2Oyd-Mk[2N|A2PTN:L3G+
BAF3 cells MnTKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M3rLSFczKGh? NXex[Gx1T0l3MDC9JFAvOTJizszN NGrkelg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
Sf9 insect cells NVnEOpd2TnWwY4Tpc44h[XO|YYm= NGHUXWI3OCCvaX7z NVq3VYpjUUN3MDC9JFAvOTJ|IN88US=> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Sf9 insect cells NF36UpNHfW6ldHnvckBie3OjeR?= M3\XUFYxKG2rboO= NFLkN2pKSzVyIE2gNE4yPDZizszN MlzNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
BAF3 cells NXnmZXpHTnWwY4Tpc44h[XO|YYm= M{nXdVczKGh? MnLmS2k2OCB;IECuNVYh|ryP NFPET5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
Sf9 cells NHLmOYRHfW6ldHnvckBie3OjeR?= NXXWb5VbPjBibXnudy=> NUnXTmtDUUN3MDC9JFAvOiEQvF2= NYLaR4N2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
MV411 cells M4\ZWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYrCeYhXT0l3MDC9JFAvOjVizszN NGTNWY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
MV4-11 cells NHXsfmhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NHfzV5k4OiCq M1;qNmdKPTBiPTCwMlM{KM7:TR?= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ|MEW1N{c,OjZ4M{C1OVM9N2F-
MV4-11 cells NF3tWGJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NGTjWGM4OiCq M1zZTGdKPTBiPTCwMlM{KM7:TR?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
DOHH2 cells NHfNUJhEgXSxdH;4bYNqfHliYYPzZZk> NGDCVGo4OiCq MXfHTVUxKD1iMD60NUDPxE1? NVnaWJFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
HCC827 cells MnLRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M1G2VFk3KGh? MUfFR|UxKD1iMD60OUDPxE1? M1S3RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
SU-DHL6 cells NFGyXJNEgXSxdH;4bYNqfHliYYPzZZk> M2X0[|czKGh? M4f6OmdKPTBiPTCwMlU5KM7:TR?= Mnz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
M07e cells M4n4VWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYK5ZXF5T0l3MDC9JFAvPTlizszN NFjJO2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
NCI-H1975 cells NFn5TllCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MWW5OkBp M1zXVWVEPTBiPTCwMlY1KM7:TR?= NIPO[2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
SU-DHL-2 cells NVmx[HRWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2juVWdKPTBiPTCwMlY1KM7:TR?= NGfOS3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
HEK293T cells M4HYSmZ2dmO2aX;uJIF{e2G7 NVz3WnRTOSCq NF7aNnlKSzVyIE2gNE46KM7:TR?= NFX2WJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
Ramos cells M1LCNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MWC3NkBp NF3GXZJKSzVyIE2gNE46OiEQvF2= MnPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5MUWwNlMoRjJ7N{G1NFI{RC:jPh?=
BA/F3 cells NYrJSGxkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M4\oWVczKGh? NX60V5FWUUN3MDC9JFEh|ryP M1LjfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
WSU-NHL cells NIjDV5hEgXSxdH;4bYNqfHliYYPzZZk> NVj3TWwxPzJiaB?= MnvGS2k2OCB;IEGuNFkh|ryP MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
NCI-H1975 cells NH;EcnNHfW6ldHnvckBie3OjeR?= MlSxO|IhcA>? MX7HTVUxKD1iMT6yJO69VQ>? NGH2SYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NCI-H1975 cells MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? M2DXdVczKGh? NYLSUVhIUUN3MDC9JFEvOjdizszN NETxXGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEezOFU5OSd-Mki3N|Q2QDF:L3G+
Raji cells MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NF\zfpk1QCCq M4\5OmlEPTBiPTCxMlQ6KM7:TR?= M4j4flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NU[3Nlk2Lz5{OUW2O|I6PTxxYU6=
Pfeiffer cells NGXMb25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFLoN3ZIUTVyIE2gNU43KM7:TR?= NVXYO4VpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
A431 cells NGrDVJZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MYi5OkBp NITLSWVGSzVyIE2gNk4{QCEQvF2= NEKzVYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
BAF3 cells MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MmLFO|IhcA>? M1vTS2dKPTBiPTCyMlUh|ryP MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
U937 cells Mo\nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MofqS2k2OCB;IEKuPUDPxE1? NWjNZYJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
NB4 cells M2nWdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFe0TmpIUTVyIE2gN{DPxE1? MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Ramos cells NIrMboRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4rjc2dKPTBiPTCzMlQh|ryP MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
SKM1 cells MkHKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MknTS2k2OCB;IEOuOkDPxE1? Mkj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
U2932 cells NEPLcGNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmLiS2k2OCB;IESuOEDPxE1? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Ramos cells M4roeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M3fyNFczKGh? NUjyN|h3UUN3MDC9JFUvOTRizszN NIG0S4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
Ramos cells NYTFT4k{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MnnZOFghcA>? NG\TOmNKSzVyIE2gOU4yPCEQvF2= Ml;mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7NU[wN|coRjJ5OUW2NFM4RC:jPh?=
Ramos cells MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MWm0PEBp Mnv0TWM2OCB;IEWuPFgh|ryP MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|Mkm0Okc,Ojh2M{K5OFY9N2F-
Ramos cells M3rDWWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NFuydXU4OiCq NEDCWnFKSzVyIE2gOk43OiEQvF2= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN|Y9N2F-
K562 cells Mk\NRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M{LnfFQ5KGh? NUfYO29lUUN3MDC9JFcvPSEQvF2= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
HL60 cells NW\GSoQ3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M2XCVFQ5KGh? NY[xN3VKUUN3MDC9JFgh|ryP MlLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByN{e2NFgoRjNyMEe3OlA5RC:jPh?=
Ramos cells MoLoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NXPkfnVEPDhiaB?= NYXMfphJUUN3MDC9JFgvOTFizszN M1zlNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M3Lz5{N{m5OFc{PjxxYU6=
Ramos cells Mn\qRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MWK0PEBp MYrJR|UxKD1iOD6yOkDPxE1? NX;4VpZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OlczQTVpPkK5OVY4Ojl3PD;hQi=>
OCI-AML3 cells MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYXHTVUxKD1iOT6yJO69VQ>? NXXBeGRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
BAF3 cells MXPDfZRwfG:6aXPpeJkh[XO|YYm= Ml\jO|IhcA>? NYWyRXZ2T0l3MDC9JFExKM7:TR?= M1LwNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkOwOVU{Lz5{Nk[zNFU2OzxxYU6=
BAF3 cells M{nUN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NXPBVG1ZPzJiaB?= MVrHTVUxKD1iMUCg{txO MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3 cells NV34bmlQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXq3NkBp NYLtdYpjT0l3MDC9JFExKM7:TR?= NX3hcZpCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NAMALWA cells NUXwTYN{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NVm5R3l1PzJiaB?= MojKTWM2OCB;IEGwMlQ2KM7:TR?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN|Y9N2F-
Ramos cells NHf3WJBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NX63XYVYPDhiaB?= Mk\PTWM2OCB;IEGyMlYh|ryP NWHMT5l7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVIyPzVpPkK3PVEzOTd3PD;hQi=>
Raji cells MkPxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MV60PEBp NXPOSVBbUUN3MDC9JFE1NjJizszN NGnHWI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC3O|YxQCd-M{CwO|c3ODh:L3G+
Raji cells NXXCZXhlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= Mn7MOFghcA>? MoHKTWM2OCB;IEG1MlIh|ryP MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOkc,Ojd7OUS3N|Y9N2F-
MIAPaCa2 cells MoTOR5l1d3SxeHnjbZR6KGG|c3H5 NF\GU3c{KGSjeYO= NFjoOmFKSzVyIE2gNVYvPiEQvF2= MnnsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyN{eyNlgoRjJ5MEe3NlI5RC:jPh?=
HeLa cells MUHDfZRwfG:6aXPpeJkh[XO|YYm= NUX4No5COyCmYYnz NUXHTnlvUUN3MDC9JFE3NjhizszN MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
Raji cells MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MnvzOFghcA>? NV7RWIpHUUN3MDC9JFE6NjNizszN NFrzVmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxNlE4PSd-Mke5NVIyPzV:L3G+
Raji cells MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NHHrcIw1QCCq NUPvN49SUUN3MDC9JFE6NjNizszN NXflVJZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N|I6PDZpPkK4OFMzQTR4PD;hQi=>
Raji cells NIiwNIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NFPVPWs4OiCq Mne2TWM2OCB;IEG5MlUh|ryP NFfxOlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
Raji cells NGO3PFJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MYq0PEBp Mn[5TWM2OCB;IEG5MlUh|ryP MnvMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7NU[wN|coRjJ5OUW2NFM4RC:jPh?=
NAMALWA cells MoTWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NF\ZNos4OiCq M2LpV2lEPTBiPTCxPU43KM7:TR?= NFv1fWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
A2780 cells MVnDfZRwfG:6aXPpeJkh[XO|YYm= Mlz3N{Bl[Xm| NEDVXlZGSzVyIE2gNlAvOSEQvF2= NYf5eIVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO|czOjhpPkK3NFc4OjJ6PD;hQi=>
Raji cells M3S4cGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M37tUFczKGh? NIf2bJJKSzVyIE2gNlAvQDhizszN NFXt[|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlE{Pid-MkmxOFYyOzZ:L3G+
A549 cells M1HsfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MkPZO|IhcA>? MkfmTWM2OCB;IEKxMlc6KM7:TR?= NV;LSpRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3N|Q2QDFpPkK4O|M1PThzPD;hQi=>
SW480 cells MlXyR5l1d3SxeHnjbZR6KGG|c3H5 NFPqXFQ{KGSjeYO= MlT0TWM2OCB;IEK1MlYh|ryP NHTtV3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C3O|IzQCd-MkewO|czOjh:L3G+
Ramos cells MXjDfZRwfG:6aXPpeJkh[XO|YYm= MWKyOEBp MnHQTWM2OCB;IEK4Mlch|ryP NEC5dmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK3OFY4PSd-MkiyO|Q3PzV:L3G+

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
pEGFR(Tyr1068) / EGFR; 

PubMed: 28061447     


Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment.

pBTK / pPLCγ2 / pAKT / pERK / pJNK; 

PubMed: 23940282     


Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.

28061447 23940282
Immunofluorescence
CD11b; 

PubMed: 30231870     


BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm.

COX-2; 

PubMed: 30231870     


BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies. 

30231870
ELISA
hTNFα; 

PubMed: 26627823     


PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3).

IL-10; 

PubMed: 27792904     


LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.

26627823 27792904
体内研究

Ibrutinib 作用于胶原诱导的关节炎模型，通过抑制B细胞活性，显著降低足肿胀和关节发炎等临床关节炎症状。Ibrutinib 作用于 MRL-Fas(lpr) 狼疮模型 ,降低肾疾病和自身抗体产量。[1] Ibrutinib 每天按25 mg/kg剂量作用于过继转移TCL1 的CLL小鼠模型, 产生短暂的早期淋巴细胞增多症，且延迟CLL 疾病进展。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：

[1]
- 合并

激酶实验:

激酶, 33P-ATP, Ibrutinib, 和底物 [0.2 mg/mL 聚(EY)(4:1)]温育1小时后，使用33P 过滤结合实验测量体外激酶IC50值。
细胞实验：

[2]
- 合并
  • Cell lines: 慢性淋巴细胞白血病 (CLL) 细胞
  • Concentrations: 0.01 μM到100 μM
  • Incubation Time: 48小时
  • Method:

    进行MTT实验测定细胞毒性。细胞(CLL B 细胞或健康志愿者T 细胞或 NK细胞) 和不同浓度 Ibrutinib温育48小时。加入MTT试剂,实验板再温育20小时，然后使用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO，通过分光光度法使用Labsystems 酶标仪，在540 nm处测定吸光值。使用膜联蛋白/PI 流式细胞仪在不同时间点测量细胞活力。使用 Expo-ADC32 软件包分析数据。结果表示为总阳性细胞与对照组之比的百分数。加入100μM Z-VAD检测caspase依赖性凋亡。


    (Only for Reference)
动物实验：

[1]
- 合并
  • Animal Models: MRL-Fas(lpr) 狼疮模型和胶原诱导的关节炎模型
  • Dosages: ≤50 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 88 mg/mL (199.77 mM)
Ethanol 45 mg/mL (102.15 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5% DMSO+30% PEG 300+5% Tween 80+ddH2O
 10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 440.5
化学式

C25H24N6O2
CAS号 936563-96-1
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04876092 Recruiting Drug: JNJ-67856633|Drug: Ibrutinib Leukemia Lymphocytic Chronic B-Cell|Lymphoma Non-Hodgkin Janssen Research & Development LLC July 28 2021 Phase 1
NCT04665115 Not yet recruiting Drug: Ibrutinib|Other: Quality-of-Life Assessment Asymptomatic COVID-19 Infection Laboratory-Confirmed|B-Cell Neoplasm|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Symptomatic COVID-19 Infection Laboratory-Confirmed|Waldenstrom Macroglobulinemia Academic and Community Cancer Research United|National Cancer Institute (NCI) June 30 2021 Phase 2
NCT04294641 Recruiting Drug: Ibrutinib Chronic GVHD National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 10 2021 Phase 2
NCT04514393 Not yet recruiting Drug: Methotrexate|Drug: Ibrutinib|Drug: Temozolomide Primary Central Nervous System Lymphoma|PCNSL|Non Hodgkin Lymphoma Huiqiang Huang|Guangdong 999 Brain Hospital|Nanfang Hospital of Southern Medical University|Xian-Janssen Pharmaceutical Ltd.|Sun Yat-sen University December 1 2020 Phase 2
NCT03679624 Recruiting Drug: Ibrutinib|Drug: Daratumumab Waldenstrom Macroglobulinemia|Waldenstrom''s Disease|Waldenström; Hypergammaglobulinemia|Waldenstrom''s Macroglobulinemia Recurrent|Waldenstrom''s Macroglobulinemia of Lymph Nodes|Waldenstrom''s Macroglobulinaemia Without Mention of Remission|Waldenstrom''s Macroglobulinemia Refractory Weill Medical College of Cornell University|Janssen Scientific Affairs LLC|Mayo Clinic July 30 2020 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    How to reconstitute the compound S2680 for in vivo studies?

  • 回答：

    For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

Selleck产品目录册
Tags: 购买Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)供应商 | 采购Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)价格 | Ibrutinib (PCI-32765)生产 | 订购Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID